GPP
ARCT icon

Great Point Partners’s Arcturus Therapeutics ARCT Stock Holding History

Great Point Partners’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-69,600
Closed -$7.52M – 31
2014
Q3 		$7.52M Buy
+69,600
New +$9.07M 3.23% 14

Other funds holding ARCT

Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $214M AUM 62.74% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
VM
VHCP Management New York $93M AUM 10.04% 1-Year Est. Return
GTC
Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return
KCM
Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return

Great Point Partners's ARCT Position: Q3 2016 in Review

Great Point Partners sold out of Arcturus Therapeutics (ARCT) in Q3 2016, closing a stake of 202,082 shares — an estimated $6.35M sold.

Great Point Partners first reported a position in ARCT in Q4 2013 and held it in 9 quarters. The position peaked at $12.6M in Q4 2015. 43 funds tracked by Wall St. Rank hold ARCT as of Q3 2016.

  • Great Point Partners reported no remaining Arcturus Therapeutics position as of Q3 2016 after selling out during the quarter.
  • Great Point Partners sold 202,082 Arcturus Therapeutics shares in Q3 2016, an estimated $6.35M.
  • Great Point Partners first reported a position in Arcturus Therapeutics in Q4 2013 and held it in 9 quarters.
  • Great Point Partners's Arcturus Therapeutics position peaked at $12.6M in Q4 2015.
  • 43 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q3 2016.

Based on Great Point Partners's 13F filing for Q3 2016, filed 14 Nov 2016.